Peru

BMI View: Peru's high diabetes disease burden, the country's strong macroeconomic growth and rising consumer demand present potential opportunities for Novo Nordisk to generate robust... 2012-08-24

BMI View: Despite the downward revision to Peru's pharmaceutical market growth forecast, we maintain our view that the market has long-term attractiveness. We expect the expansion of... 2012-08-20

BMI View: Increased prevention activities and earlier introduction of treatments are important for Peru to reduce its high cancer burden and leverage government healthcare funding in... 2012-07-17

BMI View: Multinational drugmakers are in a weak position in Peru's pharmaceutical market as government policies, especially those concerning the generic drug sector, favour local competitors.... 2012-02-23

BMI View: Although healthcare funding announcements by the Peruvian government promise to introduce much needed medicines and healthcare equipment, we note that its focus on large-scale... 2011-10-31

BMI View: Despite President Ollanta Humala's government demonstrating a strong will to combat Peru's mounting healthcare problems, we maintain the view that the government's inability... 2011-10-10

BMI View: A couple of months into President Ollanta Humala's presidency, we are beginning to see hints of protectionist policies play out. While it is important to ensure that pharmaceutical... 2011-08-16